Key Players
Competitive Landscape
There are some company types competing in vascular disrupting agents through distinct clinical and licensing models today. Direct VDA developers work beside vasculature-modulating microtubule developers, partnership-led asset holders and pharmaceutical groups with legacy programs.
Investment has shifted toward secured asset financing and confirmatory registration work across active programs from 2025 onward. In January 2026, Oncotelic raised about USD 0.4 million through a secured note covering CA4P and OXi4503. In March 2026, BeyondSpring designated DUBLIN-4 as plinabulin's current global confirmatory Phase III program. Competition now depends on funded execution, partner access and survival evidence beyond an imaging response.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In January 2026, Oncotelic entered a secured note agreement for about USD 0.4 million with CA4P and OXi4503 among the secured assets. | Direct VDA developers need external capital to restart sponsor-led clinical work. | Financing terms decide which retained agents return to active development. | Partner-funded melanoma and acute myeloid leukemia studies using retained VDA assets. |
| In March 2026, BeyondSpring reported plans for the global DUBLIN-4 confirmatory Phase III study following DUBLIN-3 and FDA discussions. | Post-immunotherapy NSCLC programs need confirmatory survival evidence against docetaxel. | Vasculature-modulating programs are entering biomarker-defined registration studies. | Clinical supply, biomarker testing and site services for a 442-patient global study. |
| In September 2025, Neuphoria retained BNC105 as a partnership-led oncology asset with six completed clinical trials. | Legacy VDA assets require shared funding and development responsibility. | Asset owners preserve clinical options through licensing instead of internal spending. | Licensing, trial sponsorship and indication-specific redevelopment for BNC105. |
Bristol Myers Squibb remains relevant through combretastatin patent rights linked to Oncotelic current direct assets. AstraZeneca, Novartis, Sanofi and Abbott Laboratories provide legacy benchmarks without dated exact-market developments during the selected period.
Source: Future Market Insights, Vascular Disrupting Agents and Oncology Clinical Trials Market Reports, 2026-2036.
Oncotelic, BeyondSpring and Neuphoria cover direct VDA ownership, Phase III vasculature modulation, partnership-led development and clinical evidence across solid and hematologic cancers.
Who leads the vascular disrupting agents market?
Oncotelic leads on verified direct asset breadth through CA4P and OXi4503, although both programs require funding or collaboration. BeyondSpring leads current clinical-stage depth through plinabulin and the planned DUBLIN-4 confirmatory Phase III study.
Which companies retain direct vascular-disruption assets?
Oncotelic retains CA4P for melanoma and OXi4503 for acute myeloid leukemia under current development plans. Neuphoria retains BNC105 as a vascular tubulin polymerization inhibitor evaluated in six trials and requires partners to fund indication-specific studies.
Which companies reached the deepest clinical stages?
Novartis advanced ASA404 into Phase III, while BeyondSpring completed DUBLIN-3 and now plans DUBLIN-4 for plinabulin. AstraZeneca, Sanofi and Abbott provide earlier clinical records that clarify dose limitations and safety barriers.
Which companies hold licensing or partnership roles?
Bristol Myers Squibb licenses selected combretastatin patent rights used by Oncotelic for CA4P and OXi4503. Neuphoria seeks partners for BNC105, and Oncotelic needs financing or collaboration to return retained assets to sponsor-led studies.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Oncotelic Therapeutics, Inc. | United States | Owns CA4P and OXi4503; further work depends on capital and collaboration. |
| BeyondSpring Inc. | United States and China | Plinabulin completed DUBLIN-3; DUBLIN-4 is the planned 442-patient Phase III study. |
| Neuphoria Therapeutics Inc. | United States; legacy Australian development | BNC105 completed six trials; further work depends on development partnerships. |
| Bristol Myers Squibb Company | Global intellectual-property role | Licenses selected combretastatin patent rights used for CA4P and OXi4503. |
| AstraZeneca PLC | Global legacy trial reach | Legacy ZD6126 sponsor without a verified current exact-market program. |
| Novartis AG | Global legacy trial reach | Legacy ASA404 sponsor that reached Phase III and later ended development. |
| Sanofi | Global legacy trial reach | Legacy ombrabulin sponsor without a verified current exact-market program. |
| Abbott Laboratories | Global legacy trial reach | Legacy ABT-751 sponsor and adjacent tubulin comparator outside current direct VDA development. |
Research Methodology
The companies show how the vascular disrupting agents market is structured and do not constitute a commercial ranking. Inclusion requires current evidence linking a company to a direct VDA, a vasculature-modulating microtubule asset, a patent license or a legacy clinical program. Official filings, company announcements, trial registries and patent disclosures provide the supporting evidence for each inclusion. Legacy programs are identified separately, and the 48.0% tubulin-binding share remains an FMI estimate for 2026.
